Physician profile
Charles J Mauney
NPI 1700884558
$1,435.18
in general payments reported to CMS, 2019-2025
21 companies · $81.04 in 2025
The $81.04 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $127 · 2021: $123 · 2022: $427 · 2023: $209 · 2024: $192 · 2025: $81.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $262.36 | 2020-2023 | Krystexxa |
| Smith+Nephew, INC. | $181.49 | 2019-2025 | Collagenase Santyl |
| Melinta Therapeutics, LLC | $164.47 | 2019-2023 | Orbactiv, Kimyrsa |
| Bioventus LLC | $140.37 | 2019-2024 | Exogen Ultrasound Bone Healing System |
| Paratek Pharmaceuticals, INC. | $93.67 | 2022-2024 | Nuzyra |
| Medtronic, INC. | $78.26 | 2022-2023 | Intellis Adaptivestim |
| Organogenesis INC. | $69.55 | 2020-2024 | |
| Averitas Pharma INC. | $66.20 | 2023-2024 | Qutenza |
| Convatec INC. | $55.04 | 2024 | |
| Depuy Synthes Sales INC. | $42.50 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.21 | 2022-2025 | Jublia |
| Next Science LLC | $38.86 | 2023 | Surgx, Blastx, Xperience |
| Sebela Pharmaceuticals INC. | $37.40 | 2019-2021 | |
| Nevro Corp. | $34.08 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.85 | 2025 | Purified Cortrophin Gel |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.40 | 2025 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $22.53 | 2022 | |
| Peerless Surgical INC. | $18.01 | 2019 | |
| Nabriva Therapeutics, Plc | $15.49 | 2022 | |
| Solventum Corporation | $14.12 | 2024 | Activ.A.C., Snap, Promogran Prisma |
| Pfizer INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mauney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.